Al-Ola A Abdallah, Director of Plasma Cell Disorders Care at The University of Kansas Health System and Chair of USMIRC, shared on X:
“For clinicians treating multiple myeloma with BCMA- or GPRC5D-directed bispecific antibodies: what is your usual approach to CRS prophylaxis during step-up dosing, beyond standard premedication?”
You can also read: Ultra-Low-Dose Radiation Therapy Relieves Bone Pain From Multiple Myeloma – ASTRO
